Literature DB >> 20923719

Preventing parenteral nutrition liver disease.

Deirdre A Kelly1.   

Abstract

Parenteral nutrition liver disease (PNLD) develops in 40-60% of infants who require long-term PN for intestinal failure. The clinical spectrum includes hepatic steatosis, cholestasis, cholelithiasis, and hepatic fibrosis. Progression to biliary cirrhosis and the development of portal hypertension and liver failure occurs in a minority who require combined liver and intestinal transplantation. The pathogenesis is multifactorial and is related to prematurity, low birth weight, duration of PN, short bowel syndrome requiring multiple laparotomies and recurrent sepsis. Other important mechanisms include lack of enteral feeding which leads to reduced gut hormone secretion, reduction of bile flow and biliary stasis which leads to the development of cholestasis, biliary sludge and gallstones, which exacerbate hepatic dysfunction, especially in premature neonates with immature hepatic function. The use of lipid emulsions, particularly soy bean emulsions have been associated with hepatic cholestasis in children, although there are little data now to support toxicity from other PN components. Management strategies for the prevention of parenteral nutrition liver disease include consideration of early enteral feeding, a multidisciplinary approach to the management of parenteral nutrition with a specialized nutritional care team and aseptic catheter techniques to reduce sepsis. The use of specialized lipid emulsions such as fish oil emulsions and or SMOF (Soy bean/Medium Chain Triglyceride/Olive Oil/Fish oil) improves established cholestasis and may prevent the onset. Oral administration of ursodeoxycholic acid may improve bile flow and reduce gall bladder stasis, although there is little data to suggest that prophylactic use prevents the onset of PNLD. Survival following either isolated small bowel or combined liver and small bowel transplantation is approximately 50% at 5 years making this an acceptable therapeutic option in children with irreversible liver and intestinal failure.
Copyright © 2010. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923719     DOI: 10.1016/j.earlhumdev.2010.08.012

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  21 in total

1.  No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.

Authors:  Gustavo Villalona; Amber Price; Keith Blomenkamp; Chandrashekhara Manithody; Saurabh Saxena; Thomas Ratchford; Matthew Westrich; Vindhya Kakarla; Shruthika Pochampally; William Phillips; Nicole Heafner; Niraja Korremla; Jose Greenspon; Miguel A Guzman; Ajay Kumar Jain
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-04-27       Impact factor: 4.016

Review 2.  Short bowel syndrome in the NICU.

Authors:  Sachin C Amin; Cleo Pappas; Hari Iyengar; Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2013-01-17       Impact factor: 3.430

3.  Comparison of culture media for bile Acid transport studies in primary human hepatocytes.

Authors:  Lisa-Mari Mörk; Bengt Isaksson; Nicola Boran; Bo-Göran Ericzon; Stephen Strom; Björn Fischler; Ewa Ellis
Journal:  J Clin Exp Hepatol       Date:  2012-12-16

4.  Liver disease after intensive care of premature baboons: histopathologic observations.

Authors:  Jay Kerecman; Anupamjit Mehrotra; Zachary Goodman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-08       Impact factor: 2.839

5.  Inpatient outcomes of preterm infants receiving ω-3 enriched lipid emulsion (SMOFlipid): an observational study.

Authors:  Nalin Choudhary; Kenneth Tan; Atul Malhotra
Journal:  Eur J Pediatr       Date:  2018-02-14       Impact factor: 3.183

6.  Parenteral lipid emulsions in guinea pigs differentially influence plasma and tissue levels of fatty acids, squalene, cholesterol, and phytosterols.

Authors:  Kevin Harvey; Zhidong Xu; Candace Walker; Thomas Pavlina; Sheila McGrath; Gary Zaloga; Rafat Siddiqui
Journal:  Lipids       Date:  2014-07-06       Impact factor: 1.880

7.  Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure.

Authors:  J Pichler; V Simchowitz; S Macdonald; S Hill
Journal:  Eur J Clin Nutr       Date:  2014-06-25       Impact factor: 4.016

8.  Extraintestinal manifestations in an infant with microvillus inclusion disease: complications or features of the disease?

Authors:  Tania Siahanidou; Eirini Koutsounaki; Anna-Venetia Skiathitou; Kalliopi Stefanaki; Evangelos Marinos; Ioanna Panajiotou; Giorgos Chouliaras
Journal:  Eur J Pediatr       Date:  2013-01-25       Impact factor: 3.183

9.  Clinical problem-solving: Short bowel syndrome in an infant.

Authors:  Claude C Roy; Véronique Groleau; Mona Beaunoyer; Valérie Marchand
Journal:  Paediatr Child Health       Date:  2013-08       Impact factor: 2.253

10.  Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition.

Authors:  Ajay Kumar Jain; Abhineet Sharma; Sumit Arora; Keith Blomenkamp; Ik Chan Jun; Robert Luong; David John Westrich; Aayush Mittal; Paula M Buchanan; Miguel A Guzman; John Long; Brent A Neuschwander-Tetri; Jeffery Teckman
Journal:  JPEN J Parenter Enteral Nutr       Date:  2016-08-20       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.